MENU
HALO
Stock ticker: NASDAQ
PRICE
CHANGE
CAPITALIZATION

HALO stock forecast, quote, news & analysis

Halozyme Therapeutics Inc is a biotechnology company focused on developing and commercializing novel oncology therapies... Show more

Industry: #Biotechnology
HALO
Daily Signal:
Gain/Loss:
A.I.Advisor
published price charts
These past five trading days, the stock lost 0.00% with an average daily volume of 0 shares traded.The stock tracked a drawdown of 0% for this period. HALO showed earnings on February 17, 2026. You can read more about the earnings report here.
Interact to see
Advertisement
A.I.Advisor
a Summary for HALO with price predictions
Apr 16, 2026

HALO's RSI Oscillator ascends from oversold territory

The RSI Oscillator for HALO moved out of oversold territory on March 30, 2026. This could be a sign that the stock is shifting from a downward trend to an upward trend. Traders may want to buy the stock or call options. The A.I.dvisor looked at 34 similar instances when the indicator left oversold territory. In of the 34 cases the stock moved higher. This puts the odds of a move higher at .

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Momentum Indicator moved above the 0 level on April 07, 2026. You may want to consider a long position or call options on HALO as a result. In of 78 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .

The Moving Average Convergence Divergence (MACD) for HALO just turned positive on March 31, 2026. Looking at past instances where HALO's MACD turned positive, the stock continued to rise in of 36 cases over the following month. The odds of a continued upward trend are .

Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where HALO advanced for three days, in of 317 cases, the price rose further within the following month. The odds of a continued upward trend are .

Bearish Trend Analysis

The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 5 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where HALO declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

HALO broke above its upper Bollinger Band on April 09, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

The Aroon Indicator for HALO entered a downward trend on April 08, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Fundamental Analysis (Ratings)

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating very strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. HALO’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating well-balanced risk and returns. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock slightly better than average.

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (161.290) is normal, around the industry mean (26.524). P/E Ratio (26.027) is within average values for comparable stocks, (45.776). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (1.765). Dividend Yield (0.000) settles around the average of (0.034) among similar stocks. P/S Ratio (5.910) is also within normal values, averaging (321.098).

A.I.Advisor
published Highlights

Notable companies

The most notable companies in this group are Regeneron Pharmaceuticals (NASDAQ:REGN), Moderna (NASDAQ:MRNA), Incyte Corp (NASDAQ:INCY), Exelixis (NASDAQ:EXEL), Arrowhead Pharmaceuticals (NASDAQ:ARWR), Nektar Therapeutics (NASDAQ:NKTR), Sarepta Therapeutics (NASDAQ:SRPT), Adaptive Biotechnologies Corp (NASDAQ:ADPT), Novavax (NASDAQ:NVAX), Inovio Pharmaceuticals (NASDAQ:INO).

Industry description

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

Market Cap

The average market capitalization across the Biotechnology Industry is 2.31B. The market cap for tickers in the group ranges from 58 to 110.81B. VRTX holds the highest valuation in this group at 110.81B. The lowest valued company is SEELQ at 58.

High and low price notable news

The average weekly price growth across all stocks in the Biotechnology Industry was 4%. For the same Industry, the average monthly price growth was 4%, and the average quarterly price growth was 9%. PBM experienced the highest price growth at 134%, while ASBP experienced the biggest fall at -75%.

Volume

The average weekly volume growth across all stocks in the Biotechnology Industry was -31%. For the same stocks of the Industry, the average monthly volume growth was -35% and the average quarterly volume growth was -43%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 50
P/E Growth Rating: 83
Price Growth Rating: 56
SMR Rating: 92
Profit Risk Rating: 94
Seasonality Score: -10 (-100 ... +100)
View a ticker or compare two or three
HALO
Daily Signal:
Gain/Loss:
Interact to see
Advertisement
A.I. Advisor
published General Information

General Information

a developer of recombinant human enzymes for the infertility, ophthalmology and oncology markets

Industry Biotechnology

Profile
Details
Industry
Biotechnology
Address
12390 El Camino Real
Phone
+1 858 794-8889
Employees
373
Web
https://www.halozyme.com
HALO's RSI Oscillator ascends from oversold territory